Kiromic BioPharma Announces Settlement of Previously Disclosed SEC Investigation

KRBP 12.03.2024

SERA-AI Powered Highlights
Drug:ALEXIS-PRO-1 ProcelTM
Drug:ALEXIS-ISO-1 IsocelTM
Full Press ReleaseSEC FilingsOur KRBP Tweets

About Gravity Analytica

Recent News

  • 01.21.2025 - Kiromic BioPharma Reports Tumor Volume Decrease in Two Patients Enrolled in Deltacel-01
  • 12.12.2024 - Kiromic BioPharma Reports 32% Decrease in Tumor Volume Eight Months Post-Treatment in Fourth Patient Enrolled in Deltacel-01
  • 12.03.2024 - Kiromic BioPharma Announces Settlement of Previously Disclosed SEC Investigation

Recent Filings

  • 01.17.2025 - S-1 General form for registration of securities under the Securities Act of 1933
  • 12.11.2024 - 8-K Current report
  • 11.08.2024 - 10-Q Quarterly report [Sections 13 or 15(d)]
PDF Version

SECdeclines to impose civil penalties in light of the Company’s self-reporting, prompt remediation and cooperation

HOUSTON--(BUSINESS WIRE)--Dec. 3, 2024--Kiromic BioPharma, Inc.(OTCQB: KRBP) (“Kiromic” or the “Company”)today announced that it has entered into a settlement agreement with theU.S. Securities and Exchange Commission(the “SEC”), resolving the previously disclosedSECinvestigation arising from the non-disclosure by Kiromic’s prior executive management of the clinical holds placed on the investigational new drug (“IND”) applications the Company filed with theU.S. Food and Drug Administration(the “FDA”) inMay 2021. The IND applications pertained to ALEXIS-PRO-1 (ProcelTM) and ALEXIS-ISO-1 (IsocelTM). In light of the Company’s self-reporting, prompt remediation and cooperation, theSEChas determined not to impose a civil penalty on the Company and there are no ongoing undertakings in connection with the settlement.

AboutKiromic BioPharma

Kiromic BioPharma, Inc.is a clinical-stage, fully integrated biotherapeutics company developing a multi-indication allogeneic cell therapy platform that exploits the natural potency of Gamma Delta T-cells to target solid tumors. Kiromic is using its proprietary DIAMOND®artificial intelligence (AI) 2.0 platform to discover novel targets for immuno-oncology. The Company maintains offices inHouston, Texas. To learn more, visitwww.kiromic.comand connect with us onTwitterandLinkedIn.

View source version onbusinesswire.com:https://www.businesswire.com/news/home/20241203898249/en/

Alliance Advisors IRTirth T. Pateltpatel@allianceadvisors.com212-201-6614

Source:Kiromic BioPharma, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com